- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07228247
Étude de phase Ⅰ/Ⅱa sur le HMPL-A251 chez des participants atteints de tumeurs solides avancées ou métastatiques exprimant HER2
Une Étude de Phase Ⅰ/Ⅱa pour Évaluer la Sécurité, la Tolérance, la Pharmacocinétique, l'Immunogénicité et l'Efficacité Préliminaire de HMPL-A251 chez les Participants Atteints de Tumeurs Solides Avancées ou Métastatiques Exprimant HER2
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
- To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
- To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Beijing, Chine
- Recrutement
- Peking University First Hospital
-
Contact:
- Shikai Wu
- Numéro de téléphone: +86 18910715326
- E-mail: skywu4329@sina.com
-
Contact:
- Yu Fan
-
Changsha, Chine
- Recrutement
- Hunan Cancer Hospital
-
Contact:
- Quchang Oyang
- Numéro de téléphone: 0731-89762161
- E-mail: Oyqc1969@126.com
-
Guangzhou, Chine
- Recrutement
- Sun Yat-sen University Cancer Center
-
Contact:
- Shusen Wang
- Numéro de téléphone: 020-87342693
- E-mail: Wangshus@susucc.org.cn
-
Hefei, Chine
- Recrutement
- The First Affiliated Hospital of Anhui Medical University
-
Contact:
- Yingying Du
- Numéro de téléphone: 0551-65908511
- E-mail: duyy1980@126.com
-
Shanghai, Chine
- Recrutement
- Fudan University Shanghai Cancer Center
-
Contact:
- Jian Zhang
-
Contact:
- Xiaohua Wu
- Numéro de téléphone: 18121299168
- E-mail: wu.xh@fudan.edu.cn
-
Shenyang, Chine
- Recrutement
- The First Hospital of China Medical University
-
Contact:
- Funan Liu
- Numéro de téléphone: 13609877906
- E-mail: lfn_clinical@126.com
-
Zhengzhou, Chine
- Recrutement
- Henan Cancer Hospital
-
Contact:
- Min Yan
- Numéro de téléphone: +86 157 1385 7388
- E-mail: ym200678@163.com
-
-
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Recrutement
- SCRI HealthONE
-
Contact:
- Gerald Falchook
- Numéro de téléphone: 940-365-6217
- E-mail: bianca.reyes@scri.com
-
-
Florida
-
Plantation, Florida, États-Unis, 33322
- Recrutement
- BRCR Global
-
Contact:
- Harshad Amin
- Numéro de téléphone: 561-447-0614
- E-mail: alejandrop@brcrglobal.com
-
Plantation, Florida, États-Unis, 33322
- Recrutement
- Florida Clinical Trials Group LLC (Plantation)
-
Contact:
- Harshad Amin
- Numéro de téléphone: 772-297-3057
- E-mail: clinops@floridactg.com
-
Tamarac, Florida, États-Unis, 33321
- Pas encore de recrutement
- Florida Clinical Trials Group LLC (Tamarac)
-
Contact:
- Chintan Ghandi
-
-
New Jersey
-
East Brunswick, New Jersey, États-Unis, 08816
- Pas encore de recrutement
- START New Jersey
-
Contact:
- Bruno Fang
-
-
New York
-
New York, New York, États-Unis, 10065
- Pas encore de recrutement
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Vicky Makker
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Recrutement
- Cleveland Clinic Taussig Cancer Center
-
Contact:
- WenWee Ma
- Numéro de téléphone: 216-559-9815
- E-mail: keaneyh@ccf.org
-
-
Washington
-
Tacoma, Washington, États-Unis, 98405
- Pas encore de recrutement
- Northwest Medical Specialties, PLLC
-
Contact:
- Jorge Chaves
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Histologically confirmed unresectable advanced or metastatic disease.
- Have at least one measurable lesion per RECIST v1.1;
- Life expectancy ≥ 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
- Weight ≥ 35 kg;
Exclusion Criteria:
- An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
- Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
- Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
- Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
- Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
- Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part A(Phase I)
Dose Escalation |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
|
Expérimental: Part B(Phase IIa)
Dose Expansion/Dose Optimization |
Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Délai: Approximately 12 months
|
At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251 |
Approximately 12 months
|
|
Recommended doses for expansion (RDE)
Délai: Approximately 12 months
|
The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data. |
Approximately 12 months
|
|
Overview of Treatment-emergent Adverse Events (TEAEs)
Délai: Approximately 24 months
|
All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA). |
Approximately 24 months
|
|
Objective Response Rate (ORR)
Délai: At least 6 weeks post dose of first participant up to approximately 24 months
|
ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1. |
At least 6 weeks post dose of first participant up to approximately 24 months
|
|
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
Délai: Approximately 12 months
|
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data. |
Approximately 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease control rate (DCR)
Délai: Approximately 2 years
|
The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks. |
Approximately 2 years
|
|
Duration of response (DoR)
Délai: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause. |
Approximately 2 years
|
|
Time to response (TTR)
Délai: Approximately 2 years
|
Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR) |
Approximately 2 years
|
|
Progression-free survival (PFS)
Délai: Approximately 2 years
|
The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first. |
Approximately 2 years
|
|
Overall survival (OS)
Délai: Approximately 2 years
|
Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first. |
Approximately 2 years
|
|
Maximum plasma/serum concentration (Cmax)
Délai: Cycle 1 and Cycle 3 (21-day cycle)
|
Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3. |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Time to maximum plasma/serum concentration (Tmax)
Délai: Cycle 1 and Cycle 3 (21-day cycle)
|
Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609 |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Area under the plasma/serum concentration-time curve (AUC)
Délai: Cycle 1 and Cycle 3 (21-day cycle)
|
Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis |
Cycle 1 and Cycle 3 (21-day cycle)
|
|
Pre-dose plasma/serum concentration (Cmin)
Délai: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609. |
Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
|
|
Immunogenicity of HMPL-A251
Délai: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251 |
Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 2025-251-GLOB1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .